Equities
Health CareMedical Equipment and Services
  • Price (USD)511.30
  • Today's Change-0.97 / -0.19%
  • Shares traded360.50k
  • 1 Year change+13.55%
  • Beta1.3258
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 17-Sep-24
Select bar for recommendation details.
Recommendations17-Sep-24
Buy2
Outperform4
Hold7
Sell1
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for IDEXX Laboratories, Inc. have a median target of 542.00, with a high estimate of 607.00 and a low estimate of 405.12. The median estimate represents a 6.00% increase from the last price of 511.30.
High18.7%607.00
Med6.0%542.00
Low-20.8%405.12

Earnings history & estimates in USD

On Aug 06, 2024, IDEXX Laboratories, Inc. reported 2nd quarter 2024 earnings of 2.44 per share.
The next earnings announcement is expected on Oct 30, 2024.
Average growth rate-1.40%
IDEXX Laboratories, Inc. reported annual 2023 earnings of 10.06 per share on Feb 05, 2024.
Average growth rate+21.01%
More ▼

Revenue history & estimates in USD

IDEXX Laboratories, Inc. had 2nd quarter 2024 revenues of 1.00bn. This missed the 1.01bn consensus estimate of the 8 analysts following the company. This was 11.48% above the prior year's 2nd quarter results.
Average growth rate+1.63%
IDEXX Laboratories, Inc. had revenues for the full year 2023 of 3.66bn. This was 8.72% above the prior year's results.
Average growth rate+11.17%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.